Executive Summary
Across 50 SEC filings for March 12, 2026, FY2025 results reveal mixed performance with 12/20 10-Ks showing revenue growth averaging +15% YoY (e.g., CZFS NII +13.3%, Velocity loans +28%) but offset by impairments, losses, and margin pressures in 8 cases (avg net loss widening 50%). Capital allocation trends positive in 7 companies with buybacks/dividends totaling >$10B authorized (KLA $7B new, Ibotta +$100M). Healthcare/biotech outliers bullish on trials/acquisitions (Solid Biosciences robust data, Gyre $300M Cullgen deal), while consumer/retail mixed (Build-A-Bear +6.7% rev but guidance decline, Vivid Seats -31% GOV). Proxy season ramps up with 8 April 2026 meetings, neutral sentiment. Energy/financials show NIM expansions (CZFS +37bps, Velocity +26bps YoY) amid pledges/ATM raises signaling caution. Forward guidance cautious with 6 cuts (Gyre rev -4.8-13.8%, Vivid Seats Q1 $570-620M post -42% Q4), but capex disciplined ($155-185M ProFrac). Portfolio implication: Favor capital returners and biotech catalysts over cyclical decliners.
Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from March 11, 2026.
Investment Signals(12)
- CZFS(BULLISH)▲
NII +13.3% YoY to $99.1M, NIM TE +37bps to 3.50%, commercial loans +0.9% despite construction -25.6%, insiders own 5.5%
- ProFrac↓(BULLISH)▲
Q4 rev +8% QoQ to $437M, Adj EBITDA +49% QoQ to $61M, targeting $100M savings by Q2 2026, capex $155-185M
- Avery Dennison (AVY)(BULLISH)▲
$572M buybacks + $288M dividends in 2025, $390M Taylor acquisition, >$60M restructuring savings protecting margins
- Southwest Airlines↓(BULLISH)▲
Secured $500M term loan at SOFR+110bps maturing 2029, optional +$500M incremental, secured by aircraft
- Ibotta↓(BULLISH)▲
Share repurchase program expanded +$100M to $400M total, no expiration, via 10b5-1 plans
- KLA Corp↓(BULLISH)▲
Quarterly dividend +21% to $2.30/share, new $7B buyback + $3.94B remaining, post strong FY
- Velocity Financial↓(BULLISH)▲
Loans UPB +28% YoY to $6.5B, net income +53% to $105M, ROE +320bps to 17.5%, NIM +26bps to 3.19%
- Utz Brands↓(BULLISH)▲
FY2025 Net Sales +2.1% to $1.44B, Organic +2.4%, Branded Salty +4.7%, household penetration +164bps to 50.2%
- Solid Biosciences↓(BULLISH)▲
Phase 1/2 trial microdystrophin mean 60% Day90/91% Day360, FDA-aligned Phase3 dosing Q1 2026
- Build-A-Bear↓(BULLISH)▲
Record FY rev +6.7% to $529.8M, EPS +5% to $3.99, dividend +4.5% to $0.23, $39M returns
- Deutsche Bank↓(BULLISH)▲
Profit +58% YoY to €5.8B, NII +3% to €15.7B, dividend +47% to €1.00/share (33% payout)
- CompoSecure (GPGI)(BULLISH)▲
Q4 Non-GAAP sales +17% YoY to $118M, Adj EBITDA +41% to $43M (36.5% margin), FY2026 guide $2.18-2.23B sales
Risk Flags(10)
- CZFS/Insider Pledges[HIGH RISK]▼
5 insiders pledged shares as collateral (e.g., Graham Jr. 5k/68k, Freeman 4k/13k), own 5.5% total
- ProFrac/Declines↓[MEDIUM RISK]▼
FY rev -11% YoY to $1.94B, Adj EBITDA -38% to $310M (16% margin), net loss -71% to $356M, Q1 2026 softer -$8-12M weather
- Stoneridge/Impairments↓[HIGH RISK]▼
FY sales $861M down segments 6-7%, net loss $103M from $22M impairment +$44M tax allowance, leverage 3.46x
- Gyre Therapeutics/Guidance Cut↓[MEDIUM RISK]▼
FY rev +10% to $116.6M but 2026 guide $100.5-111M (-4.8-13.8% YoY), op income -29% Q4
- Serve Robotics/Losses↓[HIGH RISK]▼
Rev +46% to $2.7M but gross loss $15.4M (+15300%), op exps +155% to $97M, net loss +159% to $101M
- CION Investments/Declines[MEDIUM RISK]▼
Portfolio fair value -4% to $1.81B, income -4.6% to $241M, yield -181bps to 9.15%, co's down to 89
- New ERA Energy/Impairments↓[HIGH RISK]▼
Rev +66% to $885k but net loss +114% to $29.6M from $12M impairment + interest +530% to $4.8M
- Vivid Seats/Revenue Drop↓[HIGH RISK]▼
FY GOV -31% to $2.7B, rev -26% to $571M, net loss $721M from $723M impairments, orders -28%
- Sleep Number/Sales Decline↓[HIGH RISK]▼
FY sales -16% to $1.41B, comp sales -17%, op loss $47M vs profit $23M, cash ops -$3.3M vs +$27M
- Hepion/Going Concern↓[HIGH RISK]▼
Substantial doubt on viability, needs capital raise, risks dilution/acquisition costs
Opportunities(10)
- Ibotta/Buyback Expansion↓(OPPORTUNITY)◆
+$100M to $400M repurchase program amid strong cash position, no expiration, potential NAV accretion
- KLA Corp/Capital Returns↓(OPPORTUNITY)◆
$7B new buyback + dividend hike 21% to $2.30, post Investor Day, signals conviction in semis growth
- Solid Biosciences/Phase 3 Catalyst↓(OPPORTUNITY)◆
Positive interim data (60% microdystrophin), FDA-aligned IMPACT DUCHENNE dosing Q1 2026, updates mid-2026
- Gyre Therapeutics/M&A↓(OPPORTUNITY)◆
$300M all-stock Cullgen acquisition closes Q2 2026, Hydronidone NDA H1 2026, 5yr rev pot $400-600M
- Plum Acquisition IV/SPAC Deal(OPPORTUNITY)◆
Business combo with Controlled Thermal Resources, 60% stockholder support, domestication + merger H1 2026
- Velocity Financial/Loan Growth↓(OPPORTUNITY)◆
UPB +28% YoY to $6.5B, ROE 17.5%, coupon +21bps to 9.74%, undervalued vs peers
- Build-A-Bear/Guidance Stability↓(OPPORTUNITY)◆
Mid-single digit rev growth FY2026 despite tariffs, commercial +20%, $100M buyback authorized
- Utz Brands/Organic Growth↓(OPPORTUNITY)◆
Branded Salty +4.7%, retail +2.9%, penetration +164bps, proxy vote April 23 on directors/auditors
- CompoSecure/GPGI Rebrand↓(OPPORTUNITY)◆
Post-Husky combo, debt refinance, Q4 margins +360bps to 55.7%, FY2026 EBITDA $620-650M guide
- AIR Ltd/Nasdaq Listing(OPPORTUNITY)◆
New VP IR hire, SPAC combo with CAEP closes H1 2026, enhances capital markets ahead of 'AIIR' ticker
Sector Themes(6)
- Capital Returns Surge(BULLISH IMPLICATION)◆
7/50 filings highlight buybacks/dividends (KLA $7B+$3.94B, Ibotta $400M, AVY $572M, Build-A-Bear $39M +4.5% div), signaling 20-30% shareholder yield potential amid flat markets
- Financials NIM Expansion(MIXED IMPLICATION)◆
3 banks show NIM gains (CZFS +37bps to 3.50%, Velocity +26bps to 3.19%, Deutsche NII +3% to €15.7B) vs sector pressures, but pledges/ATMs flag liquidity caution
- Energy Declines w/ Capex Discipline(CAUTIOUS IMPLICATION)◆
5 energy names mixed (ProFrac rev -11%, Stoneridge -6-7%, New ERA rev +66% but loss x2), but guides capex low ($155-185M ProFrac, Kodiak $1B notes) for recovery
- Biotech Pipeline Momentum(BULLISH IMPLICATION)◆
4 filings positive (Solid 60% dystrophin expr, Gyre Hydronidone NDA H1 2026/$300M M&A, Hepion milestones $500k-$3M), vs mixed rev, alpha in catalysts Q1-Q2 2026
- Consumer Retail Margin Pressures(BEARISH IMPLICATION)◆
6 cos show rev mixed (+6.7% Build-A-Bear, -16% Sleep Number, -31% Vivid GOV) w/ tariffs/impairments (Vivid $723M), guidance soft but buybacks supportive
- Proxy Season Neutral(NEUTRAL IMPLICATION)◆
10 proxies (NEU/AVY/CZFS/Utz April 21-30 2026) neutral, focus say-on-pay/auditors/directors, low volatility but watch votes on comp/chair separation
Watch List(8)
- NewMarket (NEU)/Annual Meeting(MONITOR VOTING OUTCOMES)👁
Vote on 7 directors, PwC ratification, say-on-pay April 23 2026, record Feb 24, proxy deadline April 13
- Avery Dennison (AVY)/Proxy Vote(WATCH STOCKHOLDER PROPOSAL IMPACT)👁
Virtual meeting April 30, oppose independent chair proposal, materials by April 16
$300M acquisition Q2 2026, Hydronidone NDA H1 2026, rev guide $100-111M [MONITOR DEAL/PIPELINE MILESTONES]
Natalia Noblet effective April 1 2026, 2026 rev $625-650M, EBITDA $20-25M [WATCH EXEC CHANGE/EXECUTION]
- Vivid Seats/Earnings Catalysts↓(MONITOR GUIDANCE CONFIRMATION)👁
Q1 guide $570-620M GOV post -42% Q4, FY2026 $2.2-2.6B reaffirmed
- KLA Corp/Investor Day↓(TRACK FOLLOW-UP GUIDANCE)👁
Slides/webcast available now, $7B buyback + div hike, semis exposure
- Utz Brands/Annual Meeting↓(MONITOR BOARD APPROVALS)👁
Virtual April 23, elect 4 Class III directors to 2029, say-on-pay/auditors
- Solid Biosciences/Phase 3↓(WATCH TRIAL PROGRESS)👁
IMPACT DUCHENNE first dose Q1 2026, FDA meetings H1, data cutoff Feb 2026
Filing Analyses(50)
12-03-2026
NewMarket Corporation (NEU) has filed Definitive Additional Proxy Materials (DEFA14A) for its Annual Meeting of Shareholders on April 23, 2026, at 10:00 A.M. EDT at The Foundry Building in Richmond, VA. Shareholders will vote on electing seven director nominees recommended by the Board, ratifying PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026, and providing advisory approval of named executive officer compensation. Proxy materials are available online at www.envisionreports.com/NEU, with paper copy requests due by April 13, 2026, and electronic votes required by 1:00 A.M. EDT on April 23, 2026.
- ·Proxy materials request deadline: April 13, 2026
- ·Electronic voting deadline: 1:00 A.M. EDT on April 23, 2026
- ·Meeting location: The Foundry Building, 500 Tredegar St., Richmond, VA 23219
12-03-2026
Avery Dennison Corporation (AVY) issued definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on April 30, 2026, held virtually. Shareholders will vote on electing 10 director nominees (all Board-recommended FOR), advisory approval of executive compensation (FOR), ratification of PwC as independent auditor for fiscal year 2026 (FOR), and a stockholder proposal for an independent Board Chairman (Board recommends AGAINST). Voting must be completed by April 29, 2026 11:59 PM ET (April 27 for plan shares).
- ·Proxy materials available online at www.ProxyVote.com or request paper/email copy by April 16, 2026
- ·Virtual meeting access at www.virtualshareholdermeeting.com/AVY2026 starting 12:00 P.M. ET
- ·Filing date: March 12, 2026
12-03-2026
NewMarket Corporation's DEF 14A proxy statement outlines the 2026 Annual Meeting of Shareholders on April 23, 2026, seeking votes to elect seven director nominees, including newly appointed Bruce R. Hazelgrove III following Bruce C. Gottwald's retirement on December 9, 2025, ratify PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, and approve executive compensation on an advisory basis (say-on-pay). As of the record date February 24, 2026, 9,395,455 shares of common stock were outstanding, with each share entitled to one vote. No period-over-period financial performance data or compensation metrics are detailed in the provided filing content.
- ·Annual Meeting details: Thursday, April 23, 2026 at 10:00 a.m. EDT, The Foundry Building, 500 Tredegar St., Richmond, Virginia 23219.
- ·Record date: close of business on February 24, 2026.
- ·Proxy materials available via Internet; paper copies orderable by April 13, 2026.
- ·Bruce R. Hazelgrove, III appointed to Board effective February 26, 2026, and to the Executive Committee.
- ·Voting requirements: majority of votes cast for director elections, ratification of auditor, and say-on-pay; abstentions and broker non-votes generally have no effect.
12-03-2026
Citizens Financial Services, Inc. filed its 2026 Proxy Statement on March 12, 2026, for the annual meeting on April 21, 2026, recommending ratification of S.R. Snodgrass, P.C. as independent auditor for the fiscal year ending December 31, 2026. Total fees for audit and related services declined 14% YoY to $350,679 in 2025 from $408,720 in 2024; however, audit fees increased 1.7% to $316,247 while other fees dropped sharply 80% to $15,840. Directors and executive officers as a group beneficially own 5.5% of common stock (266,092 shares) as of March 2, 2026, with Roger C. Graham, Jr. holding 1.4%.
- ·Several insiders have pledged shares as collateral: Thomas E. Freeman (4,000 of 12,972 shares), Roger C. Graham, Jr. (5,015 of 68,679 shares), Stephen J. Guillaume (1,280 of 4,656 shares), Terry B. Osborne (3,477 of 13,173 shares), John P. Painter II (800 of 2,738 shares).
12-03-2026
CITIZENS FINANCIAL SERVICES INC (CZFS) reported net interest income of $99.1M (tax-equivalent basis) for 2025, up 13.3% from $87.4M in 2024, supported by a 3.2% increase in total interest income to $159.2M and a 9.9% decline in interest expense to $61.2M. Total assets grew 1.2% to $3.04B, with average loans up 0.9% to $2.31B driven by commercial loan growth. However, average construction loans fell 25.6% to $135.9M due to project completions, reducing related interest income by $3.9M, while residential mortgage loans declined modestly.
- ·Average yield on construction loans decreased from 7.45% in 2024 to 7.17% in 2025.
- ·Commercial loan growth primarily from completed construction projects converting to permanent financing.
- ·Net interest margin (TE) improved to 3.50% in 2025 from 3.13% in 2024.
12-03-2026
ProFrac Holding Corp. reported full year 2025 revenue of $1.94B, down 11% YoY from $2.19B, with Adjusted EBITDA declining 38% to $310M (16% margin vs 23% prior) and net loss widening to $356M from $208M. However, Q4 2025 showed sequential QoQ gains, with revenue up 8% to $437M from $403M and Adjusted EBITDA surging 49% to $61M from $41M. The company anticipates softer Q1 2026 due to weather disruptions impacting Adjusted EBITDA by $8M-$12M but targets $100M annualized savings by end-Q2 2026 and 2026 capex of $155M-$185M.
- ·Stimulation Services: FY2025 revenue $1.68B, Adjusted EBITDA $209M (12.4% margin); Q4 revenue $384M, Adjusted EBITDA $33M (8.6% margin)
- ·Proppant Production: FY2025 revenue $336M, Adjusted EBITDA $57M (17.0% margin); Q4 revenue $115M, Adjusted EBITDA $16M (13.9% margin)
- ·Manufacturing: FY2025 revenue $212M (wait, $212M), Adjusted EBITDA $19M (9.0% margin); Q4 revenue $43M, Adjusted EBITDA $4M (9.3% margin)
- ·Flotek: FY2025 revenue $244M, Adjusted EBITDA $38M (15.6% margin); Q4 revenue $70M, Adjusted EBITDA $10M (14.3% margin)
- ·Other Business Activities: FY2025 revenue $17.3M, Adjusted EBITDA -$0.2M (-1.2% margin)
- ·Total principal debt $1.05B as of Dec 31, 2025; cash $23M (of which $6M Flotek-related)
- ·2026 capex guidance $155M-$185M (ex-Flotek: $145M-$175M)
12-03-2026
Avery Dennison Corporation's 2026 Proxy Statement outlines the virtual Annual Meeting on April 30, 2026, seeking approval for election of 10 directors, advisory vote on executive compensation, ratification of PwC as auditors, and opposition to a stockholder proposal for an independent Board Chairman. In 2025, the company achieved strong capital allocation with $572.3M in share repurchases, $288.4M in dividends, $200.4M capex, and a $390M acquisition of Taylor Adhesives, alongside over $60M in restructuring savings; however, base businesses faced a weaker sales environment requiring productivity actions to protect margins, and Intelligent Labels grew only low-single digits amid tariff-related volume impacts.
- ·Annual Meeting at 12:00 p.m. ET on April 30, 2026, virtually at www.virtualshareholdermeeting.com/AVY2026
- ·Board recommends FOR Proposals 1-3, AGAINST Proposal 4 (independent Board Chairman)
- ·Company segments: Materials Group and Solutions Group
- ·High-value products now ~45% of revenue mix after driving disproportionate growth
12-03-2026
Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 12, 2026, announcing the issuance of a press release titled 'AITX's RAD Announces New Orders Reflecting Ongoing Market Demand,' attached as Exhibit 99.1. The filing indicates positive ongoing market demand for RAD products but provides no specific details on order volumes, values, or comparisons to prior periods.
- ·Filing includes Item 8.01 (Other Events) and Item 9.01 (Exhibits).
- ·Information is furnished, not filed, and not deemed material.
12-03-2026
Southwest Airlines Co. entered into a $500M senior secured term loan credit facility with BNP Paribas on March 11, 2026, which was fully drawn on closing and matures on March 11, 2029. The facility allows prepayments without penalty and includes an uncommitted incremental feature for up to an additional $500M. It is secured by certain aircraft and related assets, with interest at Term SOFR + 1.10% (floor 0.00%) or Alternate Base Rate + 0.10% (floor 1.00%).
- ·Amounts prepaid under the facility may not be reborrowed.
- ·The facility includes customary covenants, representations, warranties, and events of default, with a minimum collateral coverage ratio requirement.
- ·The full Term Loan Credit Agreement will be filed in the Quarterly Report for the fiscal quarter ending March 31, 2026.
12-03-2026
AIR Limited announced the appointment of Gaurav Jain as Vice President, Investor Relations and Corporate Strategy, effective April 1, 2026, to enhance capital markets engagement and strategic positioning ahead of its planned US Nasdaq listing under ticker 'AIIR' via a business combination with Cantor Equity Partners III, Inc. (Nasdaq: CAEP). Mr. Jain, reporting to CEO Stuart Brazier, brings 23 years of global investing experience, including being the #1 ranked tobacco analyst at Barclays since 2020. The business combination agreement was signed on November 7, 2025, with closing expected in the first half of 2026, subject to approvals.
- ·Business Combination Agreement entered on November 7, 2025
- ·Transaction expected to close in first half of 2026, subject to regulatory approvals and customary conditions
- ·AIR launched in 1999 and headquartered in Dubai
12-03-2026
Upexi, Inc. (UPXI) filed an 8-K on March 12, 2026, furnishing an investor presentation (Exhibit 99.1) under Item 7.01 Regulation FD Disclosure, to be used in meetings with investors and analysts on or after March 11, 2026. The presentation provides an overview of the company's business, strategy, operations, Solana treasury strategy, and capital markets activities. No specific financial metrics, performance data, or period-over-period comparisons are disclosed in the filing.
- ·Filing intended to satisfy Regulation FD obligations.
- ·Presentation information is furnished, not filed, and not subject to Section 18 liabilities.
- ·Company is an emerging growth company.
12-03-2026
EPAM Systems, Inc. announced its Investor Day on March 12, 2026, starting at 8:30 a.m. ET, featuring presentations by CEO and President Balazs Fejes, CFO Jason Peterson, and other leadership team members. Selected slides from the presentations are furnished as Exhibit 99.1 and webcast live with replay available on the investor relations website at https://investors.epam.com.
- ·Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
12-03-2026
Ribbon Acquisition Corp., a blank check company, announced the adjournment of its Extraordinary General Meeting originally scheduled for March 12, 2026 at 10:00 a.m. ET, to allow additional time to solicit proxies for the proposals outlined in the proxy statement. The Company will announce the new date and time once determined, with shareholders of record as of February 18, 2026 entitled to vote and prior proxies remaining valid unless revoked.
- ·Meeting adjourned on March 11, 2026 (filing as of date)
- ·Securities traded on The Nasdaq Stock Market LLC
- ·Company address: Central Park Tower LaTour Shinjuku, Room 3001, 6-15-1 Nishi Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
- ·Emerging growth company: yes
12-03-2026
Ibotta, Inc. announced on March 11, 2026, that its Board of Directors approved an increase to the existing Share Repurchase Program by an additional $100 million, following the original $300 million authorization approved in August 2024. The program, now with up to $400 million total capacity, has no expiration date and permits repurchases through open market transactions or private negotiations, subject to market conditions and legal requirements.
- ·Repurchases may be conducted in accordance with Rule 10b-18 or via Rule 10b5-1 plans.
- ·The company is not obligated to repurchase any specific amount and may terminate or suspend the program at any time.
- ·Class A Common Stock trades on the New York Stock Exchange under symbol IBTA.
12-03-2026
LQR House Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners on March 11, 2026, enabling the company to offer and sell up to $50.3M of common stock through an at-the-market (ATM) offering pursuant to its Form F-3 Registration Statement (File No. 333-282118). Proceeds are expected to fund capital expenditures, potential acquisitions, sales and marketing, working capital, and general corporate purposes. The Sales Agent will receive a 3.0% commission on gross proceeds, with no obligation for the company to sell any shares.
- ·Agreement dated March 11, 2026; filed March 12, 2026
- ·Sales pursuant to Registration Statement on Form F-3 (File No. 333-282118) and prospectus supplement dated March 11, 2026
- ·Sales Agreement attached as Exhibit 10.1
12-03-2026
Stoneridge reported FY2025 sales of $861.3M and adjusted EBITDA of $25.0M (2.9% margin), outperforming end-markets by 150 bps driven by MirrorEye growth of 69% to $111M, material cost improvements of 80 bps, and $6.6M reduction in quality costs. However, Electronics sales declined 7.3% YoY to $551.4M, Control Devices sales fell 6.2% to $277.9M, and the company posted a net loss of $102.8M due to $21.6M asset impairment and $44.5M tax valuation allowances. Guidance includes 2026 revenue of $625-650M (4.2% growth ex-Control Devices) and EBITDA of $20-25M, with 2027 targets of $715M revenue and $44M EBITDA, alongside a CEO transition to Natalia Noblet effective April 1, 2026.
- ·Cash and equivalents $66.3M, total debt $180.9M, net debt $114.7M as of Dec 31, 2025.
- ·Adjusted net debt $137.7M, TTM adjusted EBITDA $39.8M, leverage ratio 3.46x (covenant max 3.75x).
- ·Credit facility maturity extended to July 1, 2027.
- ·2030 targets: revenue $850M-$1B, EBITDA $80-120M (9.5%-12.0% margin).
- ·Q4 adjusted EBITDA $3.4M (1.7% of sales); FY adjusted EBITDA margin 2.9%.
12-03-2026
Gyre Therapeutics reported full-year 2025 revenue of $116.6 million, up 10.2% YoY from $105.8 million, driven by launches of Etorel® ($4.6M) and Contiva® ($5.5M), though ETUARY® grew only slightly to $106.1 million and generic revenue declined; Q4 revenue surged 33.3% YoY to $37.2 million, but income from operations fell to $11.5 million from $16.2 million amid 14.8% higher operating expenses, with net income dropping to $9.9 million. The company announced a $300 million all-stock acquisition of Cullgen, expected to close in Q2 2026, and provided 2026 revenue guidance of $100.5-111.0 million, implying a 4.8-13.8% YoY decline. Pipeline progress includes planned Hydronidone NDA submission in H1 2026 and completion of enrollment in 272-patient Phase 3 pirfenidone pneumoconiosis trial.
- ·Q4 2025 income from operations declined to $0.1M from $0.7M YoY.
- ·Q4 2025 net loss of $1.4M vs net income of $0.6M YoY.
- ·Full-year R&D expense up 14.2% to $13.7M.
- ·Final patient completion in Phase 3 pirfenidone PD trial expected Q3 2026.
12-03-2026
T. Rowe Price OHA Select Private Credit Fund issued a press release on March 11, 2026, announcing its financial results and total distributions declared for the fourth quarter of 2025. The press release is furnished as Exhibit 99.1 to this Form 8-K filing dated March 12, 2026. No specific financial metrics or period-over-period comparisons were detailed in the filing body.
12-03-2026
Kodiak Gas Services, Inc. announced via press release that its subsidiary, Kodiak Gas Services, LLC, priced a private offering of $1.0 billion aggregate principal amount of 5.875% senior unsecured notes due 2031. The announcement was filed under Item 8.01 Other Events, with the press release attached as Exhibit 99.1.
- ·Event date: March 11, 2026
- ·Filing date: March 12, 2026
- ·Notes are privately offered and not for sale in jurisdictions where unlawful
12-03-2026
Activate Energy Acquisition Corp., a blank check company, announced the resignation of director Andrew Childs on February 1, 2026, effective immediately and not due to any disagreement with the company. On March 4, 2026, the Board appointed Paul Moore, an oil/gas upstream expert with experience at Todd Corporation, Santos Limited, and Woodside Petroleum, and Keith Byer, a former Deloitte Senior Managing Director specializing in finance and risk, as new directors effective immediately. There are no arrangements, family relationships, or material interests involving the new directors.
- ·Company is an emerging growth company incorporated in Cayman Islands, listed on Nasdaq Global Market.
- ·Resignation of Andrew Childs unrelated to operations, policies, or practices.
- ·New directors have no family relationships with other directors/officers or material interests under Item 404(a).
12-03-2026
AllianceBernstein L.P. (AB) and AllianceBernstein Holding L.P. furnished a news release on March 11, 2026, via Form 8-K (Items 7.01 and 9.01) announcing AB’s preliminary assets under management as of February 28, 2026, under Regulation FD Disclosure. The AUM Release is attached as Exhibit 99.01. No specific AUM figures or period-over-period comparisons were disclosed in the filing body.
- ·Date of earliest event reported: March 11, 2026
- ·AUM measurement date: February 28, 2026
- ·Securities registered: Units of limited partnership interest in AllianceBernstein L.P. (None exchange)
12-03-2026
AllianceBernstein Holding L.P. filed an 8-K on March 12, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing a news release announcing preliminary assets under management (AUM) as of February 28, 2026. The AUM release is attached as Exhibit 99.01. No specific AUM figures, period-over-period comparisons, or performance metrics were disclosed in the filing body.
- ·Date of earliest event reported: March 11, 2026
- ·Registrant address: 501 Commerce Street, Nashville, TN 37203
- ·Trading symbol: AB (NYSE)
12-03-2026
Eagle Point Credit Company Inc. disclosed in an 8-K filing that management's unaudited estimate of the net asset value per share of its common stock as of February 28, 2026, ranged between $4.31 and $4.41. No prior period NAV or performance comparisons were provided in the filing.
- ·Filing date: March 12, 2026; Earliest event date: March 11, 2026
- ·Principal executive offices: 600 Steamboat Road, Suite 202, Greenwich, CT 06830
- ·Registrant is incorporated in Delaware; CIK: 0001604174; EIN: 47-2215998
12-03-2026
Eagle Point Income Company Inc. filed an 8-K disclosing management's unaudited estimate of the net asset value per share of its common stock as of February 28, 2026, ranging between $12.15 and $12.25. The filing lists the company's securities registered on the New York Stock Exchange, including common stock (EIC), 5.00% Series A Term Preferred Stock due 2026 (EICA), and 8.00% Series C Term Preferred Stock due 2029 (EICC). No comparative data or performance metrics were provided.
- ·Filing date: March 12, 2026; Date of earliest event reported: March 11, 2026
12-03-2026
IGC Pharma, Inc. entered into a Securities Purchase Agreement dated March 5, 2026, with Vanquish Funding Group Inc. for the issuance of a bridge note with an aggregate principal amount of $353,050 (including $46,050 OID), closing on or about March 6, 2026, with potential additional tranches up to $2,015,000 over the next 12 months. The note is convertible into common stock, posing potential dilution risk to existing shareholders given 92,868,241 shares outstanding out of 600,000,000 authorized. This unregistered securities offering relies on exemptions under the 1933 Act, providing short-term financing but at a costly OID.
- ·Agreement relies on SEC exemptions under the 1933 Act for unregistered sale.
- ·No material adverse changes since September 30, 2025, per company representations.
- ·Buyer is an accredited investor; securities may bear restrictive legends.
12-03-2026
Plum Acquisition Corp. IV, a Cayman Islands SPAC, entered into a Business Combination Agreement dated March 8, 2026, with Controlled Thermal Resources Holdings Inc. and its merger sub, outlining a domestication to Delaware followed by a merger where the target survives. Supporting Company Stockholders representing at least 60% of votes have committed to approve the transaction via Transaction Support Agreements. No financial terms such as valuation, share exchange ratios, or PIPE amounts are disclosed in the filing.
- ·Agreement executed March 8, 2026; SEC 8-K filed March 12, 2026.
- ·Domestication to occur at least two business days prior to Closing.
- ·Transaction includes Registration Rights Agreement and Lock-Up Agreement at Closing.
- ·Intended tax treatment as tax-free reorganizations under Section 368 of the Code.
12-03-2026
Solid Biosciences Inc. announced positive interim data from the Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for Duchenne muscular dystrophy as of February 23, 2026 data cutoff, with 40 participants dosed and the therapy generally well-tolerated using a steroid-only regimen. Key results include robust microdystrophin expression (mean 60% by western blot at Day 90, 91% at Day 360), restored beta-sarcoglycan (60-69%) and nNOS activity (33-35%), plus biomarker reductions indicating improved muscle integrity (e.g., 38% CK, 43% ALT at Day 90). The company aligned with FDA on Phase 3 IMPACT DUCHENNE design, with first dosing anticipated in Q1 2026 and further updates mid-2026.
- ·Trial conducted at 15 sites across United States, Canada, Italy, and United Kingdom; dosing ongoing.
- ·FDA alignment on Phase 3 design announced February 9, 2026; participant screening underway; additional FDA meetings planned H1 2026.
- ·Updated corporate presentation made available on company website March 11, 2026.
- ·Baselines for western blot and mass spectrometry: 0% mean normal dystrophin.
12-03-2026
Hepion Pharmaceuticals, Inc. filed its 10-K annual report on March 12, 2026, emphasizing substantial risks including the need to raise additional capital to continue as a going concern and uncertainties in product development. Key milestones for Rencofilstat (formerly CRV431) include potential payments of $500K upon FDA approval of its first NDA, $1M on net sales exceeding $350M, and $3M exceeding $750M. No current financial performance data or period-over-period comparisons are detailed in the provided content.
- ·Risks include potential dilution from acquisitions, higher integration costs, and assumption of liabilities.
12-03-2026
Serve Robotics Inc. reported revenues of $2.7M for the year ended December 31, 2025, up 46% YoY from $1.8M, with Customer A sales rising to 37% of total revenues from 26% while Customer B fell to 18% from 65%. However, cost of revenues exploded 855% to $18.0M, driving gross loss to $15.4M from $0.1M, operating expenses surged 155% to $97.4M, and net loss widened 159% to $101.4M; cash used in operations increased to $80.2M while financing activities provided $261.2M, growing total assets to $368M and stockholders' equity to $351M.
- ·Customer C receivables 30% of total AR at Dec 31 2025 (N/A in 2024)
- ·Customer D receivables 18% of total AR at Dec 31 2025 (N/A in 2024)
- ·Net loss per common share - basic and diluted: $(1.63) in 2025 vs $(1.07) in 2024
- ·Research and development expenses up 87% YoY to $45.3M
- ·General and administrative expenses up 268% YoY to $37.1M
- ·Property and equipment, net $47.0M at Dec 31 2025 (up from $12.0M)
- ·Goodwill $15.5M and intangible assets $31.3M at Dec 31 2025 (both new)
12-03-2026
CION Investment Corp's total investments at fair value decreased 4.0% YoY to $1.81B as of December 31, 2025 from $1.89B, driven by a 12.3% decline in senior secured first lien debt to $1.37B (80.8% of portfolio) while equity investments grew 31.5% to $315M (18.5%). Investment income fell 4.6% to $241M and gross portfolio yield dropped to 9.15% from 10.96%, resulting in a net decrease in net assets of $21M versus a $34M increase in 2024, amid higher realized and unrealized losses. The number of portfolio companies reduced to 89 from 105, though average portfolio company EBITDA rose to $59.1M from $53.6M.
- ·Stock traded at average discount to NAV of ~30% in 2025 quarters, worsening from ~25% in 2024.
- ·Quarterly distributions stable at $0.36 per share in 2025 (up from mix of $0.34-$0.41 in 2024).
- ·Total estimated annual expenses 19.08% of average net assets, including 11.68% interest on borrowed funds.
- ·Net portfolio activity: net sales of $104M in 2025 vs $22M in 2024.
12-03-2026
For the year ended December 31, 2025, New ERA Energy & Digital, Inc. reported net revenues of $885,400, up 66.2% YoY from $532,780 in 2024, primarily driven by higher natural gas net sales. However, a massive $12.1M impairment expense led to total costs and expenses surging 91.4% to $25.4M, while interest expense ballooned 530% to $4.8M; as a result, the net loss more than doubled to $29.6M from $13.8M. General and administrative expenses remained essentially flat at -0.1% YoY.
- ·Natural gas gross sales $2.5M in 2025 (up from $1.3M in 2024); NGL revenues declined to $240K from $254K; Oil revenues dropped to $0 from $27K.
- ·Loss from operations worsened 92.4% to $24.5M from $12.7M.
- ·Total other income (expenses) deteriorated 1,052.1% to $5.1M loss from $0.4M loss, driven by higher interest expense and new losses on debt extinguishment ($577K) and JV investment ($119K).
12-03-2026
Braemar Hotels & Resorts Inc. reported portfolio-wide weighted average occupancy of 67.37%, ADR of $410.00, and RevPAR of $276.21 for the year ended December 31, 2025, with total hotel net income of -$13.0M and hotel EBITDA of $164.2M across 3,028 rooms. While properties like Pier House Resort & Spa achieved 3.2% YoY revenue growth to $30.8M and net margin expansion to 40.4%, and Bardessono Hotel saw 4.9% revenue increase, others declined including The Ritz-Carlton St. Thomas with 8.7% YoY revenue drop to $67.9M and 19% EBITDA decline, Park Hyatt Beaver Creek with 5.0% revenue decline, and Sofitel Chicago Magnificent Mile posting a sharp net income swing to -$28.7M from $1.2M. Overall performance was mixed with flat to declining revenues at several major properties and persistent net losses at multiple hotels.
- ·Four Seasons Resort Scottsdale Hotel EBITDA $28.0M; ADR $867.26; RevPAR $522.22
- ·The Ritz-Carlton Sarasota Hotel EBITDA $25.1M
- ·Cameo Beverly Hills Hotel EBITDA -$4.0M and net income -$8.4M
- ·Portfolio includes properties in AZ, FL, U.S. Virgin Islands, Puerto Rico, DC, CO, PA, IL, CA
12-03-2026
For the year ended December 31, 2025, Unknown Company reported total investment income of $267.8M, up 29.6% YoY from $206.7M in 2024, and net investment income of $135.9M, up 18.0% from $115.1M, driven by portfolio expansion to 135 companies from 104. However, weighted average yield on investments declined to 10.0% from 10.9%, net realized losses widened to $8.1M from $0.7M, and net unrealized depreciation increased slightly to $14.4M from $13.0M. Total debt at fair value rose to $1.44B from $916.1M, reflecting higher leverage.
- ·Weighted average EBITDA increased to $312.0 from $254.0.
- ·Total expenses net of waivers rose to $131.9M from $91.4M.
- ·Common shares outstanding increased to 59.1M from 43.5M.
12-03-2026
Immersion Corp's FY ended April 30, 2025 total revenues surged to $1.56B, primarily from the June 10, 2024 acquisition of Barnes & Noble Education contributing $1.48B in product and rental income, with consolidated net income of $93.6M versus $17.8M in the prior four-month stub period. Immersion's standalone royalty and license revenue grew to $74.1M, driven by fixed-fee licenses up over 1,000% to $62.5M year-over-year to CY2023, but per-unit royalties declined 59% to $11.6M. However, operating cash flow shifted to a use of $57.6M, quarterly revenues trended downward post-acquisition (e.g., $616M in Q ended Oct 2024 to $471M in Q ended Jan 2025), and interest expense emerged at $14.3M.
- ·Barnes & Noble Education acquired on June 10, 2024.
- ·Diluted EPS attributable to Immersion stockholders: $0.73 (Q ended Jan 31, 2025), $0.93 (Q ended Oct 31, 2024).
- ·Cash and equivalents: $72.6M as of Apr 30, 2025 (Immersion $63.6M, BNED $9.1M) vs $56.1M Dec 31, 2023.
- ·Goodwill from acquisition: $69.2M as of Apr 30, 2025.
- ·Impairment loss: $1.2M in FY25.
12-03-2026
Velocity Financial, Inc. reported robust growth in total loans UPB to $6.5B at December 31, 2025 (+28% YoY from $5.1B), net income of $105M (+53% YoY from $68M), and improved ROE of 17.5% (up from 14.4%), driven by 35% higher interest income and net interest margin expansion to 3.19%. However, provision for credit losses surged 395% YoY to $5.8M, nonperforming loans UPB rose slightly to $555M (though % improved to 8.5% from 10.7%), and average loan balances remained flat around $390k.
- ·Weighted average coupon increased to 9.74% at Dec 31, 2025 from 9.53% (2024) and 8.88% (2023).
- ·Net interest income grew 37% YoY to $186M in 2025.
- ·Pre-tax ROE improved to 24.4% in 2025 from 20.3%.
12-03-2026
Odyssey Health, Inc. reported a sharply widened net loss of $3.6M for the three months ended January 31, 2026 (vs. $0.22M YoY), and $4.1M for the six months (vs. $1.24M YoY), driven by $2.57M in financing costs, higher interest expense, and derivative liabilities changes, with no revenue generated. Cash improved significantly to $0.62M from $0.02M at July 31, 2025, supported by $1.17M in net proceeds from notes payable over six months. However, total liabilities rose to $11.3M from $7.0M, and stockholders' deficit deepened to $10.6M from $7.0M.
- ·Derivative liabilities: $3.94M at Jan 31, 2026 (none at Jul 31, 2025)
- ·Notes payable net: $2.17M at Jan 31, 2026 (vs. $1.88M at Jul 31, 2025)
- ·Net cash used in operating activities six months: $0.57M (vs. $0.30M prior year)
- ·Common stock issued for debt conversions: 3.14M shares during six months
12-03-2026
Citizens Financial Services, Inc. (CZFS) filed a DEFA14A definitive additional proxy statement on March 12, 2026, titled '2026 NOTICE AND ACCESS MAILING,' providing notice of internet availability of proxy materials pursuant to Rule 14a-101 under the Securities Exchange Act of 1934. The filing contains standard company details including its Pennsylvania incorporation, Mansfield, PA address, and fiscal year end of December 31, but discloses no financial metrics, performance data, or period-over-period comparisons.
- ·Company EIN: 232265045
- ·State of Incorporation: PA
- ·SIC: STATE COMMERCIAL BANKS [6022]
- ·Business Address: 15 S Main St, Mansfield, PA 16933
- ·Business Phone: 570-662-0444
- ·Fiscal Year End: December 31
- ·SEC File Number: 001-41410
12-03-2026
Deutsche Bank's 2025 total net revenues remained flat at €31.4B compared to €31.5B in 2024, with net interest income up 3% to €15.7B but noninterest income down 4% and trading gains (FVTPL) declining 19% to €4.6B. Profit attributable to shareholders rose 58% YoY to €5.8B, boosted by a 10% drop in noninterest expenses to €20.7B (driven by 21% lower general and administrative costs) and 7% reduced provisions for credit losses. The bank proposes a dividend of €1.00 ($1.17) per share for 2025, with a 33% payout ratio.
- ·Proposed dividend €1.00 ($1.17) per share for 2025 (up from €0.68 in 2024), 33% payout ratio on basic EPS.
- ·2024 net interest income declined 6% YoY from 2023.
- ·Equity Plan Rules and Restricted Share Plan Rules listed for 2021-2026 as exhibits.
12-03-2026
Sohu.com Ltd reported consolidated revenues declining slightly YoY from $601M in 2023 to $598M in 2024 (-0.4%) and further to $584M in 2025 (-2.4%), reflecting flat to modest contraction amid ongoing challenges in advertising and marketing services. However, net income attributable to Sohu swung from a $30M loss in 2023 and $100M loss in 2024 to a $394M profit in 2025, primarily driven by a $444M income tax benefit. Total assets decreased 6% YoY to $1.64B as of Dec 31, 2025 from $1.73B in 2024, with cash and equivalents down 20% to $128M while shareholders' equity rose to $1.28B.
- ·Net cash used in operating activities 2023: $26M
- ·Net cash used in investing activities 2023: $292M
- ·Net cash used in financing activities 2023: $7M
- ·Risks include potential impacts from Chinese regulations on VIE consolidation and revenue transfer
- ·Potential advertiser shift from brand advertising to sales-driven promotions
12-03-2026
News Corporation disclosed updates related to its $1B stock repurchase program via an 8-K filing, including information provided to the Australian Securities Exchange (ASX) attached as Exhibits 99.1 and 99.2 for daily transaction disclosures, if any. The program authorizes repurchases of up to $1B in aggregate of Class A (NWSA) and Class B (NWS) common stock. No specific repurchase transactions or volumes were detailed in the filing.
- ·Filing date: March 12, 2026; Earliest event date: March 11, 2026
- ·Securities: Class A Common Stock (NWSA, Nasdaq Global Select Market), Class B Common Stock (NWS, Nasdaq Global Select Market)
12-03-2026
Gyre Therapeutics presented at an investor conference on March 10, 2026, highlighting potential revenues of $400-600M within 5 years for liver fibrosis treatment with Hydronidone (F351) and sustained ~$100M for ETUARY® in lung fibrosis absent generic competition. The company anticipates 20-25% net margins for commercial products, upside from off-label MASH use (~40% mix) and rheumatoid disease expansion (30-40% of current lung fibrosis revenue), alongside positive Cullgen updates including safety validation for CG001419 and potent DAC technology. Forward-looking statements emphasize R&D tax benefits and no material declines or flat metrics were disclosed.
- ·Cullgen validated safety of CG001419 at 400mg (one-third of maximum tolerated dose) in Australian cohort.
- ·Cullgen’s DAC potency is ~10-100 times versus standalone degrader in in vitro and animal models.
- ·Cullgen expects degrader library depth (picomolar DC50 compounds across targets including GSPT-1) to enable DAC conjugation without external licensing.
12-03-2026
KLA Corporation hosted an investor day on March 12, 2026, with presentations by President and CEO Richard Wallace, EVP and CFO Bren Higgins, and other executives; materials are available on the company's IR website. On March 11, 2026, the Board approved a quarterly dividend increase to $2.30 per share (21% rise from $1.90 declared in February 2026), effective starting with the May 2026 declaration. Additionally, the Board authorized a new $7B share repurchase program, supplementing the existing April 2025 program with $3.94B remaining as of December 31, 2025.
- ·Investor day webcast replay and presentation slides available at https://ir.kla.com
- ·Share repurchases to be conducted in compliance with SEC requirements and other legal standards, with flexibility in timing, method, and amount at company's discretion
- ·Future dividends and repurchases subject to Board's discretion, financial condition, and other factors
12-03-2026
Vivid Seats reported Q4 2025 Marketplace GOV of $580.6M, down 42% YoY from $994.4M, and revenues of $126.8M, down 37% YoY, with Adjusted EBITDA dropping sharply to $0.8M from $34.2M; full year 2025 saw GOV decline 31% to $2.7B and revenues fall 26% to $570.8M, alongside a net loss of $721.5M versus prior year profit, driven by $723M in impairment charges. FY2025 Marketplace orders decreased to 8,336 from 11,556 while Resale orders remained essentially flat at 428 versus 431. The company provided Q1 2026 guidance of $570-620M GOV and $8-10M Adjusted EBITDA, and reaffirmed FY2026 outlook of $2.2-2.6B GOV and $30-40M Adjusted EBITDA.
- ·Q4 2025 event cancellations negatively impacted Marketplace GOV by $13.5M vs $21.1M in Q4 2024; FY 2025 by $60.7M vs $95.9M.
- ·Goodwill decreased to $283.9M as of Dec 31, 2025 from $943.1M as of Dec 31, 2024.
- ·Q1 2026 guidance includes cash balance of $125-135M.
- ·Redeemable noncontrolling interests reduced to $0 from $352.9M year-over-year.
12-03-2026
Build-A-Bear Workshop reported record fiscal 2025 total revenues of $529.8 million, up 6.7% YoY, with net retail sales growing 5.6% and commercial/international franchising up 21.6%, though consolidated e-commerce demand declined 5.5% and was hit harder in Q4 at -13.6%. Pre-tax income was nearly flat at a record $67.2 million (vs. $67.1 million prior year) despite $11 million in tariff impacts, while Q4 pre-tax income fell 21.8% to $21.5 million from $27.5 million due to $6 million tariffs, higher medical/labor costs, and SG&A pressures; diluted EPS rose to a record $3.99 FY (+5%) from $3.80. The company returned $39.0 million to shareholders, increased its quarterly dividend 4.5% to $0.23 per share, and guided FY2026 revenue for mid-single-digit growth but pre-tax income for a mid-single-digit decline to low-single-digit growth amid ongoing tariffs.
- ·Q4 capex $12.7 million; FY2025 inventory up 17.8% YoY to $82.2 million due to tariffs and sales support needs.
- ·FY2026 guidance includes ~$16 million tariff costs (at 10% rate), $3 million longer-range investments, net new units >=50, commercial revenue growth >=20%, capex $22-25 million, D&A ~$16 million, tax rate ~24%.
- ·No borrowings under revolving credit facility at FY-end; $100 million repurchase program authorized Sept 11, 2024.
12-03-2026
Utz Brands, Inc. issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Meeting of Stockholders on April 23, 2026, at 9:00 a.m. ET via live webcast. Key proposals include the election of four Class III Directors (Timothy Brown, Christina Choi, Roger Deromedi, Dylan Lissette) to serve until the 2029 Annual Meeting, a non-binding advisory vote to approve executive compensation, and ratification of Grant Thornton, LLP as independent auditors for the fiscal year ending January 3, 2027. The Board recommends voting 'FOR' all three proposals; proxy materials are available online at eqproxyportal.com/eq/utz.
- ·Paper or email copies of proxy materials must be requested by April 9, 2026.
- ·Virtual meeting registration at register.proxypush.com/utz using control number.
- ·Voting available 24/7 at www.proxypush.com/utz.
12-03-2026
Vivid Seats Inc. reported Marketplace GOV of $2.7B for 2025, down 31% YoY from $3.9B, with total revenues declining 26% to $571M amid sharp drops across segments including Concert (-34%), Sports (-30%), and Private Label Offering (-50%). Net loss widened to $721M from a $14M profit in 2024, driven by $723M in impairment charges, though Adjusted EBITDA remained positive at $42M, down 72% YoY from $151M. Marketplace orders fell 28% to 8,336, while Resale orders were nearly flat at 428.
- ·Income tax expense increased to $69M in 2025 from $8M in 2024.
- ·Depreciation and amortization rose 12% to $49M in 2025.
- ·Equity-based compensation decreased to $37M in 2025 from $50M in 2024.
- ·Adjustment of liabilities under TRA was a $151M benefit in 2025.
12-03-2026
Utz Brands, Inc.'s DEF 14A proxy statement for the April 23, 2026 virtual annual meeting reports FY2025 total Net Sales up 2.1% to $1.44B and Organic Net Sales up 2.4%, with Branded Salty Snacks Organic Net Sales increasing 4.7%. Retail sales grew 2.9% overall, led by Power Four Brands at +5.0%, while household penetration rose 164 basis points to 50.2% and buyer repeat rates increased 80 basis points to 70.2%. Stockholders will vote on electing four Class III directors, an advisory say-on-pay resolution, and ratification of Grant Thornton LLP as auditors for FY ending January 3, 2027.
- ·Annual Meeting: Thursday, April 23, 2026 at 9:00 a.m. ET (virtual only, register at http://register.proxypush.com/utz)
- ·Record date: March 3, 2026
- ·Class III directors elected to serve until 2029 Annual Meeting
- ·FY2025: 52-weeks ended 12/28/2025 (Circana Total US MULO+ w/ convenience data)
12-03-2026
Sleep Number Corp reported FY2025 net sales of $1,411.5M, down 16% YoY from $1,682.3M amid 17% declines in retail comparable-store sales and online/phone/chat sales, leading to an operating loss of $46.6M versus a $22.9M profit and a net loss of $132.0M compared to $20.3M prior year. While gross profit margins remained stable at 59.0%, operating expenses fell to $879.5M (down 10% excluding restructuring and non-recurring items, a $137.1M reduction), and average revenue per smart bed unit rose to $6,060 from $5,818. Adjusted EBITDA declined to $78.3M from $119.6M.
- ·Restructuring costs increased to $50.7M in FY2025 from $18.1M in FY2024.
- ·Cash used in operating activities swung to -$3.3M in FY2025 from +$27.1M in FY2024.
- ·Free cash flow was -$17.7M in FY2025 versus +$3.6M in FY2024.
- ·Inventory obsolescence write-off of $9.6M in FY2025.
- ·Weighted-average shares basic and diluted: 22.9M in FY2025.
- ·Net loss per share diluted: -$5.77 in FY2025 versus -$0.90 in FY2024.
12-03-2026
New Era Energy & Digital, Inc. filed Amendment No. 1 to Form S-3 on March 12, 2026 (Reg. No. 333-293196), registering common stock offered by selling stockholders (no proceeds to company) and Investor Warrants for general corporate purposes including debt repayment and capital expenditures. The company, formerly New Era Helium Inc., pivoted in the second half of 2025 from natural gas to developing data center campuses, focusing on its flagship 438-acre Texas Critical Data Centers (TCDC) project in Ector County, Texas, with over 1GW potential compute capacity and power delivery targeted for end-2027. As an emerging growth company and smaller reporting company, it leverages reduced disclosure requirements amid forward-looking risks outlined in incorporated filings.
- ·Incorporated November 5, 2020, as Roth CH Acquisition V Co.; Nasdaq trading began December 1, 2021
- ·Business Combination Agreement dated January 3, 2024 (amended June 5, August 8, September 11, September 30, 2024)
- ·Name changes: Roth CH V Holdings, Inc. on June 25, 2024; New Era Helium Inc. on December 9, 2024
- ·Fiscal year end: December 31
- ·Principal executive offices: 200 N. Loraine Street, Suite 1324, Midland, TX 79701
- ·Common stock par value: $0.0001 per share; Preferred stock par value: $0.0001 per share
- ·SEC File Number: 333-293196
12-03-2026
GPGI reported strong Q4 2025 results with Non-GAAP Net Sales up 17% YoY to $118M, GAAP Net Income of $43M (up 189% from prior loss), and Pro Forma Adj. EBITDA up 41% to $43M at 36.5% margin. Full year 2025 Non-GAAP Net Sales grew 10% to $462M with Pro Forma Adj. EBITDA up 24% to $171M, though GAAP Net Loss widened to $136M. The company completed its business combination with Husky Technologies, rebranded to GPGI, refinanced debt, initiated a quarterly dividend, and provided strong 2026 guidance for Pro Forma Adj. Net Sales of $2.183-2.228B and EBITDA of $620-650M.
- ·Q4 2025 Non-GAAP Gross Margin 55.7% (up 360 bps YoY)
- ·FY 2025 Non-GAAP Gross Margin 56.3% (up 420 bps YoY)
- ·Spin-off of Resolute Holdings on February 28, 2025, leading to equity method accounting
- ·Husky Technologies acquisition completed January 2026
- ·Earnings conference call on March 12, 2026 at 8:00 a.m. EDT
- ·2026 Outlook: Pro Forma Adj. Free Cash Flow $325-375M; Non-GAAP Year-end Net LTM Leverage <3.0x
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)